**Table 1: Summary of the characteristics of the 37 studies fulfilling the inclusion criteria.**

|  |  |  |
| --- | --- | --- |
| Characteristic | Studies, n | (%) |
| Study Design: | | |
| Prospective case series | 9 | (24) |
| Retrospective case series | 19 | (51) |
| Diagnostic case–control (two–gate series) | 4 | (11) |
| Design unclear | 5 | (14) |
| Population characteristics: |  |  |
| Sample size (participants) | \*50.4 | †(12 to 181) |
| Sample size (lesions) | \*52.3 | †(14 to 146) |
| Prevalence of malignancy (%) | \*38.1 | †(13 to 74) |
| Mean age (years; 29 studies) | ‡\*55.8 | †(44.1 to 66.7) |
| Female participants (%; 31 studies) | \*49.4 | †(6 to 87) |
| Mean tumor size (mm; 24 studies) | ‡\*41.9 | †(22 to 68.1) |
| Mean % symptomatic participants (5 studies) | \*36 | †(26 to 47) |
| Confirmed hormone excess (%; 11 studies) | \*36.3 | †(0.02 to 88) |
| Index Tests and Thresholds: |  |  |
| CT | **16** | **(43)** |
| Non–enhanced tumor density | *13* | *(35)* |
| Contrast enhanced washout studies | *6* | *(16)* |
| MRI | **15** | **(41)** |
| Chemical shift loss of signal intensity | *8* | *(22)* |
| Adrenal:liver ratio signal intensity | *8* | *(22)* |
| Adrenal:spleen ratio signal intensity | *5* | *(14)* |
| Adrenal:muscle ratio signal intensity | *2* | *(5)* |
| PET | **4** | **(11)** |
| SUVmax | *3* | *(8)* |
| SUVmax adrenal:liver ratio | *5* | *(14)* |
| PET–CT | **5** | **(14)** |
| SUVmax | *3* | *(8)* |
| ALR maxSUV | *4* | *(11)* |
| Population grouping for analysis: |  |  |
| Initial finding incidental in ≥ 90% included participants | 3 | (8) |
| Initial finding incidental in 50–90% included participants | 4 | (11) |
| Initial indication for imaging due to known cancer in ≥ 90% included participants | 9 | (24) |
| Initial indication for imaging due to known cancer in 50 to 90% included participants | 2 | (5) |
| Initial finding incidental in <50% OR <50% imaging indication known cancer | 2 | (5) |
| Population composition not reported | 17 | (46) |
| Reference Standard: |  |  |
| Histology alone | 16 | (43) |
| Histology and imaging follow to up | 15 | (41) |
| Histology and imaging follow to up, plus other reference | 5 | (14) |
| Histology plus other reference | 1 | (3) |

CT – Computed Tomography; MRI – Magnetic Resonance Imaging; PET – Positron Emission Tomography; SUVmax – maximum standardized uptake value; ALR maxSUV - ratio of SUVmax in the adrenal gland compared to the liver.

\* Mean

† Range

‡ Mean of reported means